γδ-Enriched CAR-T Cells for Bone-Targeted Adoptive Immunotherapy

Time: 2:30 pm
day: Day Two

Details:

• PSCA-targeted Vγ9Vδ2 CAR-T cells recognize and destroy prostate cancer cells.
• Vγ9Vδ2 CAR-T cells display maximum cytotoxic capacity when administered in combination with zoledronate.

Speakers: